Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.

@article{Perez2012PredictabilityOA,
  title={Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.},
  author={Edith A. Perez and Amylou C Dueck and Ann E. McCullough and Monica M. Reinholz and Kathleen S. Tenner and Nancy E. Davidson and Julie R. Gralow and Lyndsay N. Harris and Leila A. Kutteh and David W. Hillman and R. Brian Jenkins and Beiyun Chen},
  journal={Journal of the National Cancer Institute},
  year={2012},
  volume={104 2},
  pages={159-62}
}
The 2007 American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) joint guidelines defined criteria for HER2 positivity of tumors that modified those of the US Food and Drug Administration (FDA), causing some confusion and uncertainty among clinicians. Using data from the HER2-positive breast cancer adjuvant trial N9831, we compared eligibility for patients who met both criteria, and disease-free survival (DFS) was assessed by Cox proportional hazards regression… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
33 Citations
14 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 14 references

Checking the Cox model with cumulative sums of martingale - based residuals

  • DY Lin, LJ Wei, Z Ying
  • Histopathology
  • 2003

Similar Papers

Loading similar papers…